← Russell 3000 cross-section

BLFS BIOLIFE SOLUTIONS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.8bn
Revenue TTM
$103m
Net income TTM
$58m
Free cash flow
Composite score
39.1
Sector rank
#1694

Valuation

P / E
31.4
EV / EBITDA
372.9
EV / sales
16.9
FCF yield
Earnings yield vs 10-yr
-1.55pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
56.4%
EBITDA margin
4.5%
ROE
13.8%
ROIC
0.9%
Revenue growth
43.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our products Our bioproduction products and services are comprised of one revenue line that contains three main offerings: • Cell processing and other products ◦ Biopreservation media ◦ Human platelet lysate media (“hPL”), cryogenic vials, and automated cell-processing fill machines ◦ Automated thawing devices Critical accounting policies and estimates A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. …BIOLIFE SOLUTIONS INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →